Paul Tudor Jones’s Kite Pharma, Inc. KITE Stock Holding History

Paul Tudor Jones’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,055	Closed	-$524K	–	1358
2017 Q2	$524K	Buy	+5,055	New	+$412K	0.02%	556
2016 Q4	–	Sell	-6,388	Closed	-$357K	–	1753
2016 Q3	$357K	Buy	+6,388	New	+$356K	0.01%	923
2015 Q2	–	Sell	-3,767	Closed	-$217K	–	1781
2015 Q1	$217K	Buy	+3,767	New	+$252K	0.01%	1253

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Paul Tudor Jones's KITE Position: Q3 2017 in Review

Paul Tudor Jones sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 5,055 shares — an estimated $524K sold.

Paul Tudor Jones first reported a position in KITE in Q1 2015 and held it in 3 quarters. The position peaked at $524K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Paul Tudor Jones reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Paul Tudor Jones sold 5,055 Kite Pharma, Inc. shares in Q3 2017, an estimated $524K.
Paul Tudor Jones first reported a position in Kite Pharma, Inc. in Q1 2015 and held it in 3 quarters.
Paul Tudor Jones's Kite Pharma, Inc. position peaked at $524K in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Tudor Investment Corp's 13F filing for Q3 2017, filed 14 Nov 2017.